Christof Scheid, Diderik-Jan Eikema, Michel Van Gelder, Urpu Salmenniemi, Johan Maertens, Jakob R Passweg, Didier Blaise, Jennifer L Byrne, Nicolaus Kroeger, Katja Sockel, Patrice Chevallier, Jean Henri Bourhis, Jan J Cornelissen, Henrik Sengeloev, Jürgen Finke, John A Snowden, Tobias Gedde-Dahl, Jerôme Cornillon, Urs Schanz, Amit Patel, Linda Koster, Liesbeth C de Wreede, Patrick J Hayden, Kavita Raj, Joanna Drozd-Sokolowska, Carmelo Gurnari, Francesco Onida, Donal P McLornan, Marie Robin, Ibrahim Yakoub-Agha
In MDS patients higher IPSS-R at transplant is associated with worse transplant outcome. Thus, it may seem beneficial to improve IPSS-R by therapeutic intervention prior to transplantation in order to "down-stage" the disease risk. However, there is no evidence to date to support this approach. A retrospective analysis of the EBMT transplant registry was performed to investigate the role of therapeutic interventions prior to transplantation with regard to changes in IPSS-R and transplant outcomes. A total of 1482 MDS patients with sufficient data to calculate IPSS-R at diagnosis and at time of transplantation were selected and analysed for transplant outcome in a multivariable Cox model including IPSS-R at diagnosis, treatment intervention, change in IPSS-R before transplant and several patient and transplant variables...
May 10, 2024: Blood